Arax Advisory Partners’s Nuvectis Pharma NVCT Stock Holding History

Arax Advisory Partners’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-38	Closed	-$229	–	4398
2025 Q3	$229	Buy	+38	New	+$261	﹤0.01%	3437

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Arax Advisory Partners's NVCT Position: Q4 2025 in Review

Arax Advisory Partners sold out of Nuvectis Pharma (NVCT) in Q4 2025, closing a stake of 38 shares — an estimated $229 sold.

Arax Advisory Partners first reported a position in NVCT in Q3 2025 and held it in 1 quarter. The position peaked at $229 in Q3 2025. 48 funds tracked by Wall St. Rank hold NVCT as of Q4 2025.

Arax Advisory Partners reported no remaining Nuvectis Pharma position as of Q4 2025 after selling out during the quarter.
Arax Advisory Partners sold 38 Nuvectis Pharma shares in Q4 2025, an estimated $229.
Arax Advisory Partners first reported a position in Nuvectis Pharma in Q3 2025 and held it in 1 quarter.
Arax Advisory Partners's Nuvectis Pharma position peaked at $229 in Q3 2025.
48 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.